Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q1

4544.TEDINET S100RLNC
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥56.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥65.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income−¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥8.6bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income−¥1.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.5bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥1.2bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥8.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥289.6bnat 2023-06-30Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥278.3bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥139.8bnat 2023-06-30Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥149.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥146.0bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥32.7bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥32.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥39.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥6.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥4.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.7bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-19.672023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥98.252022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥98.242022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio51.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥1.6bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥36.1bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥36.1bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥18m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥2.8bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥13.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.3bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-06-30¥7.2bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.2bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-06-30¥355m
—segment totalrevenue2023-04-01 → 2023-06-30¥58.0bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
—segment totalsegment profit2023-04-01 → 2023-06-30−¥121m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥607m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥27m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥15.0bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-06-30¥440m
—segment totalrevenue2022-04-01 → 2022-06-30¥68.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥65.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 459
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant83506000000JPY
Noncurrent liabilitiesCurrentQuarterInstant86794000000JPY
LiabilitiesPrior1YearInstant147877000000JPY
LiabilitiesCurrentQuarterInstant139803000000JPY
Capital stockPrior1YearInstant9274000000JPY
Capital stockCurrentQuarterInstant9278000000JPY
Capital surplusPrior1YearInstant24996000000JPY
Capital surplusCurrentQuarterInstant25001000000JPY
Retained earningsPrior1YearInstant112422000000JPY
Retained earningsCurrentQuarterInstant107697000000JPY
Treasury stockPrior1YearInstant-2060000000JPY
Treasury stockCurrentQuarterInstant-1662000000JPY
Shareholders equityPrior1YearInstant144633000000JPY
Shareholders equityCurrentQuarterInstant140315000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant118000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant378000000JPY
Foreign currency translation adjustmentPrior1YearInstant7140000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant10897000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1919000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1875000000JPY
Valuation and translation adjustmentsPrior1YearInstant5339000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant9400000000JPY
Subscription rights to sharesPrior1YearInstant74000000JPY
Subscription rights to sharesCurrentQuarterInstant71000000JPY
Net assetsPrior1YearInstant150047000000JPY
Net assetsCurrentQuarterInstant149787000000JPY
Liabilities and net assetsPrior1YearInstant297924000000JPY
Liabilities and net assetsCurrentQuarterInstant289590000000JPY
Net salesPrior1YTDDuration65331000000JPY
Net salesCurrentYTDDuration56620000000JPY
Cost of salesPrior1YTDDuration40435000000JPY
Cost of salesCurrentYTDDuration41643000000JPY
Gross profitPrior1YTDDuration24896000000JPY
Gross profitCurrentYTDDuration14976000000JPY
Selling general and administrative expensesPrior1YTDDuration16315000000JPY
Selling general and administrative expensesCurrentYTDDuration16687000000JPY
Operating incomePrior1YTDDuration8580000000JPY
Operating incomeCurrentYTDDuration-1711000000JPY
Interest income noiPrior1YTDDuration24000000JPY
Interest income noiCurrentYTDDuration104000000JPY
Dividends income noiPrior1YTDDuration27000000JPY
Dividends income noiCurrentYTDDuration62000000JPY
Foreign exchange gains noiPrior1YTDDuration598000000JPY
Foreign exchange gains noiCurrentYTDDuration744000000JPY
Other noiPrior1YTDDuration158000000JPY
Other noiCurrentYTDDuration103000000JPY
Non operating incomePrior1YTDDuration809000000JPY
Non operating incomeCurrentYTDDuration1015000000JPY
Interest expenses noePrior1YTDDuration95000000JPY
Interest expenses noeCurrentYTDDuration95000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass